Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Resource Library

Transitioning Patients from Flolan to Veletri

Stephanie Harris


F. Springsteen

Reviews

  Sign in to add a review

0 comments
Leave a Comment

Conference: 2012 International PHA Conference and Scientific Sessions

Release Date: 06.22.2012

Presentation Type: Abstracts

Harris, S.J. RN BSN, Springsteen, F.

University of Washington Medical Center, Accredo Health Group, INC

PURPOSE: To evaluate the clinical stability of Pulmonary Arterial Hypertension (PAH) patients transitioning from Flolan to Veletri.

BACKGROUND: Epoprostenol is a prostacyclin used to treat patients with PAH, and is available from 3 different manufacturers. The drug is administered by continuous IV infusion with a pump. There are 2 different formulations, one that requires patients to keep their medication cassettes cold with ice packs, and another that allows for room temperature stability at certain concentrations. This evaluation used a small number of patient transitions to determine if the product with stability at room temperature, maintains the benefits and effectiveness of the other alternative.

METHODOLOGY: Three (3) Class IIIa IPAH patients stable on temperature sensitive epoprostenol for greater than 2 years were chosen. One patient was transitioned in the hospital, while the other 2 were monitored and transitioned in the home. Transition was accomplished by changing cassettes without withdrawing dwell volume from catheter. Vital signs, including blood pressure, heart rate, respiratory rate and O2 saturations, were obtained pre-cassette switch, then at 15, 30, 45and 60 min post cassette change. Patient follow up at 24 hours and 1 week post transition were made by phone call to discuss any issues with transitioning.

FINDINGS: There were no significant transition issues, including no adverse events, in any of the 3 patients. All Vital signs remained stable and O2 saturations remained within the patient’s usual range. Patients reported no difference in how they felt after transitioning in the 24 hr and 1 week follow-up calls.

IMPLICATIONS: Transitioning patients to the room temperature stable epoprostenol was well tolerated in these three patients. Two out of the three patients were transitioned safely in their home setting, offering convenience and cost savings.